{"id":"W2110707581","doi":"10.1016/s0140-6736(11)61226-9","title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","year":2011,"lang":"en","type":"article","venue":"The Lancet","topic":"Bone health and treatments","field":"Medicine","cited_by":797,"is_retracted":false,"has_abstract":false,"ca_institutions":"London Health Sciences Centre; Université de Montréal","funders":"National Cancer Institute","keywords":"Denosumab; Medicine; Prostate cancer; Hazard ratio; Clinical endpoint; Bone metastasis; Internal medicine; Placebo; Oncology; Interim analysis; Metastasis; Urology; Cancer; Surgery; Randomized controlled trial; Osteoporosis; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04760585834281855,"score_gpt":0.3215406155219578,"score_spread":0.2739347571791392,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}